TriangleFOR PATIENTS · SOURCE READING
Treatment of Progressive, Refractory, or Recurrent Childhood LCH in Children
Source: Langerhans Cell Histiocytosis Treatment (PDQ®)–Patient Version, National Cancer Institute.
Source updated: June 6, 2024 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary. Independent clinical review is pending.
For information about the treatments listed below, see the Treatment Option Overview section.
Source links and citations
Treatment of progressive, refractory, or recurrent low-risk LCH may include:
Source links and citations
Chemotherapy with or without steroid therapy.
Source links and citations
Bisphosphonate therapy.
Source links and citations
Treatment of progressive, refractory, or recurrent high-risk multisystem LCH may include:
Chemotherapy.
Targeted therapy (vemurafenib).
Source links and citations
Stem cell transplant.
Source links and citations
Treatments being studied for progressive, refractory, or recurrent childhood LCH include the following:
A clinical trial that tailors the patient's treatment based on features of the LCH at diagnosis and how it responds to treatment.
Source links and citations
A clinical trial of targeted therapy (trametinib and dabrafenib).
Source links and citations
Preserved source evidence · Independent clinical review pending · Not medical advice